BCAL Diagnostics (ASX:BDX) Insider Ownership : 0.00 % (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BCAL Diagnostics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BCAL Diagnostics's Institutional Ownership is 0.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BCAL Diagnostics's Float Percentage Of Total Shares Outstanding is 0.00%.

BCAL Diagnostics Insider Ownership Historical Data

The historical data trend for BCAL Diagnostics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Insider Ownership Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Insider Ownership

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Insider Ownership	Get a 7-Day Free Trial			-	-	-	-	-

BCAL Diagnostics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.